Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Phase 3

Completed

Conditions: Genital Neoplasms, Female
Fallopian Tube Neoplasms
Ovarian Neoplasms
Pelvic Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Gemcitabine
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2005-09-19

Last Posted Date: 2011-03-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 919

Registration Number: NCT00191646

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Malignant Tumor of Peritoneum

First Posted Date: 2005-09-19

Last Posted Date: 2011-02-25

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 165

Registration Number: NCT00189566

Locations: 🇫🇷
Hôpital Hotel Dieu, Paris, France

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Phase 2

Terminated

Conditions: Estrogen Receptor-positive Breast Cancer
Stage IIIA Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

Interventions: Drug: exemestane
Drug: triptorelin pamoate
Drug: capecitabine
Drug: methotrexate
Drug: vinorelbine tartrate
Drug: paclitaxel
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2005-09-19

Last Posted Date: 2017-07-11

Lead Sponsor: University of Washington

Target Recruit Count: 28

Registration Number: NCT00194792

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Phase 3

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2005-09-19

Last Posted Date: 2014-01-10

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 976

Registration Number: NCT00189553

Locations: 🇫🇷
Hôpital Hôtel Dieu, Paris, France

Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2015-03-18

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 250

Registration Number: NCT00193310

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-positive Breast Cancer
Progesterone Receptor-negative Breast Cancer
Progesterone Receptor-positive Breast Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
HER2-positive Breast Cancer
Stage IIIA Breast Cancer
Stage II Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: paclitaxel
Biological: filgrastim
Drug: capecitabine
Drug: methotrexate
Drug: vinorelbine tartrate
Procedure: needle biopsy
Procedure: therapeutic conventional surgery
Other: immunohistochemistry staining method
Biological: trastuzumab
Drug: tamoxifen citrate
Drug: letrozole
Other: laboratory biomarker analysis

First Posted Date: 2005-09-19

Last Posted Date: 2018-03-12

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT00194779

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2005-09-19

Last Posted Date: 2010-03-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT00191854

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey

Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin

Phase 2

Completed

Conditions: Ovarian Carcinoma

First Posted Date: 2005-09-16

Last Posted Date: 2022-04-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00181701

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: SU011248
Drug: Paclitaxel

First Posted Date: 2005-09-15

Last Posted Date: 2009-01-27

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00174434

Locations: 🇺🇸
Pfizer Investigational Site, New York, New York, United States

PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

Phase 1

Completed

Conditions: Carcinoma, Non-Small Cell Lung

First Posted Date: 2005-09-15

Last Posted Date: 2006-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT00174356

Locations: 🇨🇦
Pfizer Investigational Site, Hamilton, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy